8hon MSN
CEO Brian Lian highlighted 2024 as an exceptionally busy year, with successful results from four studies, including the Phase 2 VENTURE trial for subcutaneous VK2735, which demonstrated up to 14.7% ...
Readings that the podcast’s guests say shaped their thinking.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback